Imiglitazar

DB12511InvestigationalSmall molecule

Imiglitazar has been used in trials studying the treatment of Diabetes Mellitus.

Mechanism: Pharmacologically active on Peroxisome proliferator-activated receptor alpha and Peroxisome proliferator-activated receptor gamma
Curator reviewed
Formula / weight: C₂₈H₂₆N₂O₅ · 470.525 g/mol (avg)
Code names: TAK-559

Resolves to

Compound

Structure

InChIKeyULVDFHLHKNJICZ-QCWLDUFUSA-NSMILESCC1=C(COC2=CC=C(CO\N=C(/CCC(O)=O)C3=CC=CC=C3)C=C2)N=C(O1)C1=CC=CC=C1

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

14+ReferencesStructured and connected to the statements they support

Which drugs share a target with Imiglitazar, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.